Showing results 1 to 2 of 2
| Title | Author(s) | Issue Date | |
|---|---|---|---|
KEYNOTE-495/KeyImPaCT, a randomized, phase 2, biomarker-directed trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) Proceeding/Conference:Annals of Oncology | 2019 | ||
KEYNOTE-495/KeyImPaCT: Interim Analysis of a Randomized, Biomarker-Directed, ProgramsPhase 2 Trial of Pembrolizumab-Based Combination Therapy for Non–Small Cell Lung Cancer Proceeding/Conference:The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) | 2021 |